- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Patent holdings for IPC class A61K 31/517
Total number of patents in this class: 6730
10-year publication summary
|
388
|
402
|
416
|
482
|
495
|
558
|
473
|
593
|
520
|
268
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genentech, Inc. | 4099 |
100 |
| Boehringer Ingelheim International GmbH | 4493 |
83 |
| The Regents of the University of California | 20720 |
79 |
| Novartis AG | 10263 |
74 |
| F. Hoffmann-La Roche AG | 7836 |
57 |
| Bristol-myers Squibb Company | 4729 |
54 |
| AstraZeneca AB | 2818 |
47 |
| Merck Patent GmbH | 5725 |
47 |
| Array BioPharma Inc. | 447 |
47 |
| Gilead Sciences, Inc. | 2220 |
47 |
| Amgen Inc. | 4425 |
45 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
45 |
| Hoffmann-La Roche Inc. | 3783 |
43 |
| Astellas Pharma Inc. | 1043 |
43 |
| Celgene Corporation | 1411 |
43 |
| Kadmon Corporation, LLC | 107 |
42 |
| Sunshine Lake Pharma Co., Ltd. | 626 |
42 |
| Board of Regents, The University of Texas System | 6102 |
41 |
| Merck Sharp & Dohme LLC | 3735 |
40 |
| Resverlogix Corp. | 54 |
36 |
| Other owners | 5675 |